Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Kyowa Hakko Kirin Co., Ltd Patents
Assignee:
Kyowa Hakko Kirin Co., Ltd
Address:
Tokyo, JP
No. of patents:
109
Patents:


1 2 3










Patent Number Title Of Patent Date Issued
8574574 Pharmaceutical composition comprising antibody composition which specifically binds to CCR4 November 5, 2013
A pharmaceutical composition, comprising an antibody composition which specifically binds to human CC chemokine receptor 4 (hereinafter also referred to as CCR4) and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody a
8568725 Method of treating transplant rejection with an anti-CD40 antibody October 29, 2013
A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the
8283450 Human monoclonal antibody human CD134 (OX40) and methods of making and using same October 9, 2012
The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Inve
8273738 Imidazole derivatives September 25, 2012
A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I): ##STR00001## [wherein, R.sup.1 represents optionally substituted lower alkyl or the like; R.sup.2 represents optionally substituted cycloalkyl or the like; R.sup.3 represents optiona
8268592 Anti-system ASC amino acid transporter 2 (ASCT2) antibody September 18, 2012
An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as "ASCT2") or a method using the antibody. The present invention provides a monoclonal
8242151 Tricyclic compounds August 14, 2012
The present invention provides a PPAR .gamma. agonist comprising, as an active ingredient, a tricyclic compound represented by the formula (I) ##STR00001## (wherein R.sup.1 represents lower alkyl optionally having substituent(s) or the like, R.sup.2 and R.sup.3 are the same or different
8236841 Fused heterocycle derivative August 7, 2012
A fused heterocycle derivative represented by the general formula (I): ##STR00001## (wherein R.sup.1 represents optionally substituted lower alkyl, or the like; R.sup.2 represents an optionally substituted aliphatic heterocyclic group, or the like; R.sup.3 represents --C(.dbd.Z)NR
8236314 Agonist antibody to human thrombopoietin receptor August 7, 2012
This invention provides an agonist antibody to a human thrombopoietin receptor (human c-Mpl), and pharmaceutical compositions comprising the same for use in treatment of thrombocytopenia. The disclosed agonist antibody comprises (1) antibody constant regions comprising heavy and ligh
8232377 Method for high-level secretory production of protein July 31, 2012
This invention provides a means for enabling high-level secretory production of proteins, in particular proteins having complicated structures such as antibodies, in host cells such as yeast cells. The invention also provides transformed yeast cells having the activated HAC1 gene and
8222284 Stable formulations of thiadiazole derivative July 17, 2012
The present invention provides formulation parameters and manufacturing conditions for stable pharmaceutical compositions comprising N-{4-(2,2-dimethyl-propionyl)-(5R)-5-[(2-ethylamino-ethanesulfonylamino)-- methyl]-5-phenyl-4,5-dihydro-[1,3,4]thiadiazol-2-yl}-2,2-dimethyl-propiona- mi
8202869 Method of treating an anxiety disorder June 19, 2012
Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A.sub.2A recept
8197814 Method for treating the Th2-mediated disease June 12, 2012
A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereo
8192736 Remedy for endometriosis June 5, 2012
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
8173781 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth fa May 8, 2012
Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
8163282 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth fa April 24, 2012
Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
8158760 Glycoengineered, recombinant antibody April 17, 2012
The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the
8143058 Human CDR-grafted antibody and antibody fragment thereof March 27, 2012
A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically
8134015 Compound inhibiting in vivo phosphorous transport and medicine containing the same March 13, 2012
An objective of the present invention is to provide compounds that can effectively suppress the concentration of phosphorus in serum to effectively prevent or treat diseases induced by an increase in concentration of phosphate in serum. The compounds according to the present inventio
8124406 Method for modifying chromosomes February 28, 2012
The present invention relates to a method for producing a modified foreign chromosome(s) or a fragment(s) thereof, which comprises the steps of: (a) preparing a microcell comprising a foreign chromosome(s) or a fragment(s) thereof, and transferring said foreign chromosome(s) or a fra
8124091 Human monoclonal antibodies to influenza M2 protein and methods of making and using same February 28, 2012
Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. A human monoclonal antibody that binds to influenza M2 protein having different amino acid sequences. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolat
8110671 Isolated human chromosome 14 fragment encoding immunoglobulin genes February 7, 2012
The specification relates to a method for producing a chimeric non-human animal, which comprises preparing a microcell containing a foreign chromosome(s) or a fragment(s) thereof and transferring the foreign chromosome(s) or fragment(s) thereof into a pluripotent cell by fusion with
8110195 Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing gangli February 7, 2012
The present invention relates to a cell for the production of an antibody molecule such as an antibody binding to ganglioside GM2, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the ce
8101185 Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation January 24, 2012
The present invention relates to a cell for the production of an anti-IL-5 antibody molecule having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an an
8093362 Anti-PERP recombinant antibody January 10, 2012
An antibody which binds to a polypeptide encoded by human PERP (p53 apoptosis effector related to PMP-22) gene which is considered to be related to incidence of cancer or the like is desired. The present invention provides a gene recombinant antibody which has no consensus sequence o
8093361 Anti-perp antibody January 10, 2012
The present invention provides an antibody which specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by PERP (p53 apoptosis effector related to PMP-22) gene and binds to the extracellular region. The antibody of the present invention is
8076462 Method for producing antithrombin composition December 13, 2011
The provision of an antithrombin composition having a desired .alpha.-form content rate or .beta.-form content rate is required. The invention provides a process for producing an antithrombin composition having a desired .alpha.-form content rate or .beta.-form content rate which is
8076458 Anti-claudin-4 antibody December 13, 2011
An object of the present invention is to provide a monoclonal antibody which is useful as a diagnostic agent or a therapeutic agent for a disease relating to a polypeptide encoded by Claudin-4 (hereinafter referred to as "CLDN4") gene or a polypeptide encoded by a Claudin-3 (hereinaf
8071128 Intrabuccally rapidly disintegrating tablet and a production method of the tablets December 6, 2011
An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder mater
8067232 Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase November 29, 2011
The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the
8058287 Chemokine receptor antagonists and methods of use therefor November 15, 2011
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: ##STR00001## or physiologically acceptable sa
8048421 Agonist antibody to human thrombopoietin receptor November 1, 2011
This invention provides an agonist antibody to a human thrombopoietin receptor (alias: human c-Mpl). More particularly, this invention provides an agonist antibody to a human thrombopoietin receptor, wherein the agonist antibody comprises: antibody constant regions comprising (1) ami
8039595 Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation October 18, 2011
The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the
8003106 Human monoclonal antibodies to influenza M2 protein and methods of making and using same August 23, 2011
Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subj
7998954 Pyrimidodiazepinone derivative August 16, 2011
The invention provides a pyrimidodiazepinone derivative represented by the general formula (I) ##STR00001## [wherein n represents 1 or 2, Z represents a hydrogen atom or the like, R.sup.1 and R.sup.2 may be the same or different, and each represents a hydrogen atom or the like, A r
7994290 Effector function enhanced recombinant antibody composition August 9, 2011
The present invention relates to a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-depend
7981419 Method for treating hypophosphatemic bone diseases using FGF-23 antibody July 19, 2011
A method for treating a hypophosphatemic bone disease, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition, which contains an antibody that binds to an FGF-23 polypeptide and a pharmaceutically acceptable carrier.
7972815 Method of producing sugar chain using human G4 polypeptide July 5, 2011
The present invention provides a novel polypeptide having a .beta.1,3-N-acetylglucosaminyl transferase activity; a method for producing the polypeptide; a DNA which encodes the polypeptide; a recombinant vector into which the DNA is inserted; a transformant comprising the recombinant
7956060 Pyrimidine derivative compound June 7, 2011
The present invention provides an antitumor agent and the like, which comprises as an active ingredient, a pyrimidine derivative represented by Formula (I): ##STR00001## [wherein --X--Y--Z-- represents --O--CR.sup.3.dbd.N-- (wherein R.sup.3 represents a hydrogen atom, a substituted
7951381 Method of stimulating epithelial cell proliferation by administration of gastrointestinal prolif May 31, 2011
The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor (GIPF) polynucleotides and polypeptides. The invention further relates to the therapeutic use of GIPF to prevent or treat conditions or disorders associated with the degeneration of
7943745 Anti-CD98 antibody May 17, 2011
A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody b
7939077 Humanized antibody against fibroblast growth factor-8 and antibody fragment thereof May 10, 2011
The present invention relates to an antibody against FGF-8, particularly a humanized antibody against FGF-8 and the antibody fragment thereof, a DNA sequence encoding the above antibody or the antibody fragment, a vector comprising the DNA sequence and a host cell transformed by the
7928285 Method of producing xenogenous antibodies using a bovine April 19, 2011
In general, the invention features genetically modified non-human mammals (e.g., bovines and other ungulates), and methods of making these mammals. In particular, the invention features transgenic ungulates having reduced levels of endogenous IgM heavy chain and/or prion protein.
7928098 Therapeutic and/or preventive agents for a sleep disorder April 19, 2011
The present invention provides a therapeutic and/or preventive agent for a sleep disorder comprising, as an active ingredient, a thiazole derivative represented by the general formula (I), ##STR00001## [wherein R.sup.1 represents a five-membered aromatic heterocyclic group including
7923538 Recombinant antibody composition April 12, 2011
The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a pol
7923012 Antibody against fibroblast growth factor-23 April 12, 2011
The purpose of the present invention is to provide an antibody against fibroblast growth factor 23. The antibody is obtained by immunizing an animal with a polypeptide which comprises an amino acid sequence represented by SEQ ID NO: 1, or an amino acid sequence derived from the amino
7919517 Indazole derivatives April 5, 2011
The present invention provides a compound represented by Formula (I): ##STR00001## [wherein R.sup.1 represents CONR.sup.1aR.sup.1b (wherein R.sup.1a and R.sup.1b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or
7910611 Therapeutic agent for restenosis March 22, 2011
A therapeutic and/or prophylactic agent for restenosis, which comprises a thiadiazoline derivative represented by the general formula (0), or a pharmaceutically acceptable salt thereof: ##STR00001## [wherein, n represents an integer of 1 to 3, R.sup.0 represents aryl, --NR.sup.1CONR
7906522 2-aminoquinazoline derivatives March 15, 2011
The present invention provides 2-aminoquinazoline derivatives represented by formula (I): ##STR00001## wherein R.sup.1 and R.sup.2 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, and the like; X represents a bond or CR.su
7902234 Thiadiazoline derivative March 8, 2011
(wherein R.sup.1 and R.sup.4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R.sup.6 represents a substituted or unsubstituted
7883705 Anti FGF23 antibody and a pharmaceutical composition comprising the same February 8, 2011
To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Ac
1 2 3

 
 
  Recently Added Patents
Sock
Biological analysis arrangement and approach therefor
Bicycle shifting method
Bi-level switching with power packs
RFID device using single antenna for multiple resonant frequency ranges
Managing personal information on a network
Image processing apparatus, image display apparatus, and image processing method
  Randomly Featured Patents
Address plate for stepped wall structures
Method and apparatus for purifying water
Developing device for copier
Pallet changer for machining center
Two temperature thermostat
Composite cured silicone powder and method for the preparation thereof
Downlink power control for multiple downlink time slots in TDD communication systems
Cathode ray tube
Vacuum electrical interrupter with pull-to-close mechanism
Tire reinforcement